Adaptive Randomized study of idarubicin and cytarabine (IA) alone or with interleukin 11 (IL-11) as induction therapy in patients aged 50 or above with untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (HR-MDS).

被引：0

作者：

Giles, F ^{[1
]}

Kantarjian, H ^{[1
]}

Cortes, J ^{[1
]}

Tsimberidou, A ^{[1
]}

Faderl, S ^{[1
]}

Verstovsek, S ^{[1
]}

Thomas, D ^{[1
]}

Garcia-Manero, G ^{[1
]}

Wierda, W ^{[1
]}

Ferrajoli, A ^{[1
]}

Kornblau, S ^{[1
]}

Andreeff, M ^{[1
]}

O'Brien, S ^{[1
]}

Beran, M ^{[1
]}

Estey, E ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2003年 / 102卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4740

引用

页码：253B / 253B

页数：1

共 50 条

[21] Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)
Willemze, R.
Suciu, S.
Muus, P.
Halkes, C. J. M.
Meloni, G.
Meert, L.
Karrasch, M.
Rapion, J.
Vignetti, M.
Amadori, S.
de Witte, T.
Marie, J. P.
ANNALS OF HEMATOLOGY, 2014, 93 (06) : 965 - 975
[22] SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA plus V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Garcia-Manero, Guillermo
Othus, Megan
Pagel, John M.
Radich, Jerald P.
Fang, Min
Rizzieri, David A.
Marcucci, Guido
Strickland, Stephen A.
Litzow, Mark
Savoie, Mary Lynn
Medeiros, Bruno C.
Sekeres, Mikkael A.
Lin, Tara L.
Uy, Geoffrey L.
Powell, Bayard L.
Kolitz, Jonathan E.
Larson, Richard A.
Stone, Richard M.
Claxton, David F.
Essell, James
Luger, Selina
Mohan, Sanjay R.
Moseley, Anna
Appelbaum, Frederick R.
Erba, Harry P.
BLOOD, 2016, 128 (22)
[23] Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside
Estey, EH
Thall, PF
Giles, FJ
Wang, XM
Cortes, JE
Beran, M
Pierce, SA
Thomas, DA
Kantarjian, HM
BLOOD, 2002, 99 (12) : 4343 - 4349
[24] Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and PostHypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
Rivera, Daniel
Kadia, Tapan M.
Montalban-Bravo, Guillermo
Faderl, Stefan
Sasaki, Koji
Short, Nicholas J.
Daver, Naval
Di Nardo, Courtney D.
Masarova, Lucia
Ferrajoli, Alessandra
Jabbour, Elias J.
Borthakur, Gautham
Al Azzawi, Hind
Konopleva, Marina
Garcia-Manero, Guillermo
Andreeff, Michael
Kantarjian, Hagop
Ravandi, Farhad
Alvarado, Yesid
BLOOD, 2021, 138
[25] Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
Brunner, Andrew M.
Esteve, Jordi
Porkka, Kimmo
Knapper, Steve
Vey, Norbert
Scholl, Sebastian
Garcia-Manero, Guillermo
Wermke, Martin
Janssen, Jeroen
Traer, Elie
Loo, Sun
Narayan, Rupa
Tovar, Natalia
Kontro, Mika
Ottmann, Oliver
Naidu, Purushotham
Kurtulus, Sema
Makofske, Jessica
Liao, Serena
Mohammed, Anisa
Sabatos-Peyton, Catherine A.
Rinne, Mikael L.
Borate, Uma
Wei, Andrew H.
BLOOD, 2020, 136
[26] Clofarabine plus cytarabine (ara-C) is an active induction regimen for newly diagnosed patients (pts) ≤ age 50 with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MOS).
Faderl, S
Gandhi, V
Giles, F
Estey, E
Garcia-Manero, G
O'Brien, S
Wierda, W
Kwari, M
Craig, A
Kantarjian, HM
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 584S - 584S
[27] Anti-TIM-3 Antibody MBG453 in Combination with Hypomethylating Agents (HMAs) in Patients with High-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia: A Phase 1 Study
Brunner, Andrew
Borate, Uma
Esteve, Jordi
Porkka, Kimmo
Knapper, Steve
Vey, Norbert
Scholl, Sebastian
Wermke, Martin
Janssen, Jeroen
Traer, Elie
Chua, Chong Chyn
Narayan, Rupa
Tovar, Natalia
Kontro, Mika
Ottman, Oliver
Xu, Siyan
Sun, Haiying
Naidu, Purushotham
Szpakowski, Sebastian
Zhang, Na
Mohammed, Anisa
Rinne, Mikael
Wei, Andrew
Garcia-Manero, Guillermo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S188 - S189
[28] A phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) and gentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
Ghanem, H.
Kantarjian, H.
Garcia-Manero, G.
Ravandi, F.
Faderl, S.
Cortes, J. E.
Reyes, A.
O'Brien, S. M.
Borthakur, G.
Kadia, T. M.
Burger, J. A.
Konopleva, M.
Jabbour, E.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[29] Farnesyl transferase inhibitor (tipifarnib, zarnestra; Z) in combination with standard chemotherapy with idarubicin (Ida) and cytarabine (ara-c) for patients (pts) with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Cortes, J
Garcia-Manero, G
O'Brien, S
Verstovsek, S
Estrov, Z
Giles, F
Ravandi, F
Wright, J
Kantarjian, H
BLOOD, 2005, 106 (11) : 784A - 784A
[30] Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
Perez, Jorge M. Ramos
Kadia, Tapan M.
Montalban-Bravo, Guillermo
Faderl, Stefan
Sasaki, Koji
Daver, Naval
DiNardo, Courtney D.
Masarova, Lucia
Ferrajoli, Alessandra
Jabbour, Elias
Borthakur, Gautham
Al Azzawi, Hind
Pemmaraju, Naveen
Konopleva, Marina
Pierce, Sherry A.
Garcia-Manero, Guillermo
Andreeff, Michael
Kantarjian, Hagop M.
Ravandi, Farhad
Alvarado, Yesid
BLOOD, 2020, 136

← 1 2 3 4 5 →